Author:
Fears R.,Ferres H.,Greenwood H.,Standring R.,Valencia O.
Reference21 articles.
1. Clinical effects and kinetic properties of intravenous APSAC—anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction;Been;Int J Cardiol,1986
2. Value of myocardial defect size measured by Thallium-201 SPECT: Results of a multicenter trial comparing heparin and a new fibrinolytic agent;Maublant;J Nucl Med,1988
3. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo—controlled clinical trial;Lancet,1988
4. Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans;Nunn;Drugs,1987
5. High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: Alterations of the fibrinolytic system and clearance of fibrinolytic activity;Köhler;Haemostasis,1987
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献